Prostaglandin D2 receptor antagonist - Actelion
Latest Information Update: 27 Jun 2017
At a glance
- Originator Actelion Pharmaceuticals
- Class Antiasthmatics
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in Switzerland
- 01 Aug 2012 Prostaglandin D2 receptor antagonist is available for licensing as of 01 Aug 2012. http://www.actelion.com